Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: The Hoorn study

Clinical Chemistry

Volumn 54, Issue 8, 2008, Pages 1325-1330

  Scheffer, Peter G ^a,b   Teerlink, Tom ^a,b   Dekker, Jacqueline M ^a   Bos, Griët ^a   Nijpels, Giel ^a   Diamant, Michaela ^a,b   Kostense, Piet J ^a   Stehouwer, Coen D A ^c   Heine, Robert J ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY;

AGED; APOLIPOPROTEIN C-III; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 48949085360     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2008.103234     Document Type: Article

References (24)

1. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8.
2. Lee SJ, Moye LA, Campos H, Williams GH, Sacks FM. Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis 2003;167:293-302.
3. Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol 1996;263:32-60.
4. Marcoux C, Tremblay M, Nakajima K, Davignon J, Cohn JS. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. J Lipid Res 1999;40:636-47.
5. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceriderich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287-95.
6. Zheng C, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 2007;48:1190-203.
7. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006;114:681-7.
8. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006;113:691-700.
9. Olin-Lewis K, Krauss RM, La Belle M, Blanche PJ, Barrett PH, Wight TN, Chait A. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res 2002;43:1969-77.
10. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 2000;43:703-8.
11. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003;23:853-8.
12. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000;102:1886-92.
13. Gerber Y, Goldbourt U, Segev S, Harats D. Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case-control study. Prev Med 2003;37:18-22.
14. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003;168:81-9.
15. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population. The Hoorn Study. Diabetes Care 1995;18:1270-3.
16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
17. Chan DC, Watts GF, Barrett PH, Mamo JC, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002;48:278-83.
18. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care 2000;23:40-4.
19. Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 2002;32:429-36.
20. Fredenrich A. Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism. Diabetes Metab 1998;24:490-5.
21. Tentolouris N, Stylianou A, Lourida E, Perrea D, Kyriaki D, Papavasiliou EC, et al. High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria. J Lipid Res 2007;48:218-25.
22. Cohn JS, Rodriguez C, Jacques H, Tremblay M, Davignon J. Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE. J Lipid Res 2004;45:1572-9.
23. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.
24. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16.